The ABR Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the SK-HEP-1 human hepatocellular carcinoma cell line. This product contains a heterogeneous pool of cells carrying targeted disruptions in the ABR gene, providing a loss-of-function model to investigate ABR-dependent signaling and cellular functions. The polyclonal knockout format enables robust, population-level functional studies without the clonal selection biases inherent to monoclonal cell lines. By eliminating ABR expression, these cells enable the dissection of Rho GTPase regulatory networks in a liver cancer context, offering a versatile tool for studying tumor cell biology.
The SK-HEP-1 host cell line was originally derived from the ascites of a patient with liver adenocarcinoma and exhibits both epithelial and endothelial characteristics. As a widely employed model for hepatocellular carcinoma, SK-HEP-1 cells are highly aggressive and invasive, making them particularly suitable for studying metastasis-related processes. Their mixed phenotype reflects the complexity of hepatic tumors and provides a physiologically relevant background for investigating molecular mechanisms driving liver cancer progression. This cell line has been extensively characterized and serves as a reliable platform for CRISPR-based functional genomics.
ABR is a dual-function regulator of Rho GTPases, serving as a GAP for Rac1/Cdc42 and a GEF for RhoA. This coordinates actin dynamics, adhesion, and migration. Upstream signals from EGFR, PDGFR, GPCRs, Src, integrins, and Wnt feed into ABR. Downstream, ABR regulates Rac1, Cdc42, and RhoA, which control PAK, ROCK, LIMK, and cofilin, modulating F-actin. ABR interacts with 14-3-3, BCR, Src, and actin regulators, linking extracellular cues to cytoskeletal remodeling.
In SK-HEP-1 cells, ABR knockout disrupts Rho GTPase homeostasis, leading to aberrant actin organization and impaired motility. ABR normally suppresses Rac1/Cdc42 while activating RhoA, so its loss likely alters migratory and invasive properties characteristic of metastatic liver cancer. This model enables assessment of ABR’s role in hepatocellular carcinoma aggressiveness and metastasis. The polyclonal pool mimics tumor heterogeneity and avoids clonal artifacts, suitable for studying complex phenotypes.
This ABR knockout model is suitable for diverse functional studies, including wound healing and Transwell migration/invasion assays to quantify cell motility, and Rho GTPase activation pull-downs to assess GTPase activity. Immunofluorescence for F-actin and Western blotting for phospho-PAK and phospho-MLC illuminate cytoskeletal and signaling changes. Cell adhesion and proliferation assays (CCK-8) further define phenotypic alterations. In vivo, xenograft tumor models evaluate metastatic capacity, while RNA-seq provides transcriptomic insights. This product supports drug target validation and mechanistic studies of ABR in hepatocellular carcinoma progression and metastasis. For further information, please contact Ascent Research.
